Regeneron Reports Positive Results From COVID-19 Treatment Clinical Trial
Regeneron (NASDAQ: REGN) has moved up a few paces in the COVID-19 drug-development race. The company announced after market hours on Tuesday that its REGN-COV2 candidate has shown positive results in clinical trials.
In the first results published from the phase 1/2/3 study, Regeneron said that in the first 275 trial patients, REGN-COV2 "reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19."
Those patients were all afflicted with mild to moderate COVID-19, the disease caused by the SARS-CoV-2 coronavirus. Two different REGN-COV2 doses were administered to two distinct patient populations -- one seropositive (able to produce an immune response on their own) and the other seronegative (unable to do so adequately).
Source Fool.com
